Long-term delivery of a lysosomal enzyme by genetically modified fibroblasts in dogs.

Nat Med

Laboratoire Rétrovirus et Transfert Génétique, CNRS URA 1157, Institut Pasteur, Paris, France.

Published: April 1995

We have evaluated the feasibility and efficacy of intraperitoneal implants (neo-organs) for protein delivery in large animals. Skin biopsies were taken from four healthy dogs. Primary fibroblast cultures were transduced with a retroviral vector coding for the human beta-glucuronidase. One to six lattices each containing 10(9) skin fibroblasts were implanted into the omentum of the donor animal. Laparotomies performed at regular intervals showed vascularized neo-organs without local inflammation. Human beta-glucuronidase levels equivalent to 0.8 to 3.1% of the endogenous canine activity were detected for up to 340 days on liver biopsy samples. These results indicate that neo-organs can be considered for the long-term delivery of therapeutic proteins or enzymes in humans.

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm0495-353DOI Listing

Publication Analysis

Top Keywords

long-term delivery
8
human beta-glucuronidase
8
delivery lysosomal
4
lysosomal enzyme
4
enzyme genetically
4
genetically modified
4
modified fibroblasts
4
fibroblasts dogs
4
dogs evaluated
4
evaluated feasibility
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!